IBC Life Sciences’ is pleased to announce Kathleen A. Clouse, Ph.D., Division of Monoclonal Antibodies Director at OBP, CDER, US FDA will deliver a keynote presentation FDA Perspective on Novel Monoclonal Antibody Development Pathways on Friday, June 28 at the 8th annual Next Generation Protein Therapeutics Summit in San Diego, CA.This is a rare and valuable opportunity to hear first-hand from the FDA about their perspectives on the development of novel antibody-based molecules and scaffolds. Gain new ideas to help you engineer novel molecules and formats to meet regulatory expectations.
Dr. Clouse joins our faculty of over 30 international industry and academic experts in protein therapeutics design and development whose presentations will give you new ideas and practical strategies you can apply right away in your own laboratory.
For full program details, download the agenda. As a reader of this blog, when you register to join us and mention code NGPT13JP, you'll save 20% off the standard rate. This event is co-located with Bioconjugates: From Targets to Therapies, so you'll have access to sessions from both events!
Have any questions? Feel free to email Jennifer Pereira.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment